Sukumar Nagendran sold $942k of TSHA
President and Head of R&D at Taysha Gene Therapies, Inc.. 200,000 shares at an average of $4.71, traded Jan 12, 2026, filed Jan 14, 2026.
Score components
- +20RolePresident
- +24Trade size$942k at market
- +5Share of holdings soldSold 17% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.7%, 3m +19.0%, 6m +22.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001665124-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 12, 2026 | MOption exercise Common Stock10b5-1 | +111,324 | $0.70 | $78k | 1,117,763 | Jan 14, 2026 |
| Jan 12, 2026 | MOption exercise Common Stock10b5-1 | +88,676 | $1.71 | $152k | 1,206,439 | Jan 14, 2026 |
| Jan 12, 2026 | SOpen-market sale Common Stock10b5-1 | -200,000 | $4.71 | $942k | 1,006,439 | Jan 14, 2026 |
| Jan 12, 2026 | AGrant or award Common Stock10b5-1 | +427,000 | $0.00 | $0 | 1,433,439 | Jan 14, 2026 |
| Jan 12, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -111,324 | $0.00 | $0 | 111,359 | Jan 14, 2026 |
| Jan 12, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -88,676 | $0.00 | $0 | 474,941 | Jan 14, 2026 |
| Jan 12, 2026 | AGrant or award Employee Stock Option (right to buy)derivative10b5-1 | +274,000 | $0.00 | $0 | 274,000 | Jan 14, 2026 |
Related signals
Other insiders at Taysha Gene Therapies, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $1.2M 200,000 shares | -18% | |
| 13Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $892k 200,000 shares | -15% | |
| 37Weak | Taysha Gene Therapies, Inc. | Kamran Alam CHIEF FINANCIAL OFFICER | $7,481 1,655 shares | -0% | |
| 55Moderate | Taysha Gene Therapies, Inc. | Kamran Alam CHIEF FINANCIAL OFFICER | $485k 102,817 shares | -7% | |
| 54Moderate | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $547k 116,050 shares | -8% | |
| 63Notable | Taysha Gene Therapies, Inc. | Sean P. Nolan Chief Executive Officer | $840k 178,101 shares | -6% | |
| 40Moderate | TSHAsell Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $1.7M 370,172 shares | -33% | |
| 10Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $646k 200,000 shares | -17% | |
| 41Moderate | Taysha Gene Therapies, Inc. | Kamran Alam CHIEF FINANCIAL OFFICER | $155k 54,491 shares | -4% | |
| 39Weak | Taysha Gene Therapies, Inc. | Sukumar Nagendran President and Head of R&D | $163k 57,054 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.